Even with increased rates of vaccination against human papillomavirus (HPV) and advances in screening, cervical cancer continues to be deadly, reports CIDRAP News.
In the past 33 years, cervical cancer deaths have declined by less than 20%, with women living in low- to middle-income countries facing the highest risk, according to a recent paper in Nature Medicine, which examined the current global burden of cervical cancer and estimated rates for 2050.
“Cervical cancer continues to impose substantial disease burden among women worldwide, ranking as the third most common and the fourth deadliest malignancy among females in 2023,” wrote the Global Burden of Disease 2023 Cervical Cancer Collaborators.
Elimination might not be achieved by 2050
The scientists examined cervical cancer rates, deaths, and disability-adjusted life years (DALYs) for 204 countries to understand the status of cervical cancer worldwide.
In 2023, of the 887 000 new diagnoses of cervical cancer, there were 369 000 deaths and 13.3 million DALYs worldwide. This represents a global age-standardised incidence of 20.1 per 100 000 women, a dip of 0.4% since 1990. The death rate was 8.0 per 100 000 women, a 17.5% decline.
About 138 000 cervical cancer diagnoses occurred in low-income countries, representing about 15.5% of cervical cancer cases worldwide. Middle-income countries logged 343 000 cases of cervical cancer, 42.1% of all diagnoses worldwide.
By 2050, the authors anticipate the cervical cancer rate to be 17.4 per 100 000 women, a drop of 12.5%. Yet this estimate is higher than the age-standardised incidence for elimination set by the 2020 World Health Organisation Global Strategy to Accelerate the Elimination of Cervical Cancer.
“The critical threshold for elimination has been determined to be four cases per 100 000,” the authors said.
“However, with healthcare disruption caused by the 2019 Covid-19 pandemic and worsening global health financing landscape, how close countries will be to reaching this threshold and achieving the goal of cervical cancer elimination remains deeply uncertain.”
Study details
Global, regional and national burden of cervical cancer in 1990–2023 with forecasts to 2050: a Global Burden of Disease study
GBD 2023 Cervical Cancer Collaborators
Published in Nature Medicine on 2 November 2026
Abstract
Although highly preventable, cervical cancer remains one of the most common malignancies among women worldwide. As part of the Global Burden of Disease study, we estimated cervical cancer incidence, mortality and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 to 2023, with forecasts to 2050. In 2023, 887,000 new cases (95% uncertainty interval 682,000–1,170,000), 369,000 deaths (292,000–475,000) and 13.3 million DALYs (10.1–17.4) were estimated globally. Age-standardised incidence rate (ASIR) and age-standardised mortality rates (ASMR) were more than four and seven times higher in low- versus high-income countries. Between 1990 and 2023, global ASIR was largely stable (−0.4% (–26.6 to 34.7)), whereas ASMR changed by −17.5% (–36.2 to 13.4). All cervical cancer DALYs were attributable to human papillomavirus infection, with tobacco use contributing 5.9% (3.2–9.3) globally. By 2050, global ASIR and ASMR are forecast to change by −12.5% (–25.7 to 3.5) and −9.0% (–21.5 to 6.6) from 2024, yet absolute cases and deaths are forecast to rise by 20.2% (4.6–38.5) and 39.3% (23.6–57.3). ASIR and ASMR are forecast to remain highest in low-income countries. Intensified action is needed to accelerate progress.
CIDRAP article – Study examines cervical cancer’s global burden now and by 2050
See more from MedicalBrief archives:
HPV vaccine winning the cervical cancer war, but …
SA’s cervical cancer crisis a wake-up call
Vaccine could have prevented over 90% of HPV-related cancers
HPV jab success sees ‘almost zero chance of cervical cancer death’ – UK study
